The Indian insurance intermediary market, put at roughly $15 billion and spanning brokers, web aggregators and distribution platforms, has spent the week after September 24 answering IRDAI's commission caps by moving up the value chain rather than by cutting prices. PB Fintech, whose shares have fallen about 30 percent since the consultation paper was released and 36 percent in a single session, has set out possibilities including credit life, setting up its own insurer, and monetising adjacent businesses such as PB Wheels and PB Garages. Executives familiar with the matter, reported on September 28, said Turtlemint, InsuranceDekho and Ditto are also exploring ways to diversify beyond the traditional intermediary model, with the broader shift described as towards manufacturing, adjacent financial products and other revenue streams. On September 29, Plum's co-founder and CEO Abhishek Poddar said that if commission compression materially affects the insurance side of the business, the company will lean harder on the healthcare half that already provides about a quarter of it.

Context: the arithmetic that forces the move

The pressure is measurable rather than rhetorical. Jefferies estimates that if the proposed health and motor commission cuts are implemented as drafted, PB Fintech's non-life new-business economics could fall to around 33 to 40 percent of the original net present value, and that a 10 percent reduction in new-business commission rates would translate into a 10 to 12 percent decline in earnings. Jefferies also puts core platform expenses excluding employee stock options at about Rs 30 billion in FY26, roughly 80 percent of them variable, and Macquarie Capital reads PB Fintech's first response as cost-optimisation mode in the near term.

Variable cost is the part that cannot be cut indefinitely. If the variable base is eight-tenths of platform spend and the revenue per policy falls, the platform has to shrink volume, shrink the payout to the seller, or find revenue elsewhere. That is why manufacturing keeps appearing: an insurer's own margin is not a commission at all.

Implication: consolidation, not competition

  • The entry route is closing while the incumbent route is opening. IRDAI has tightened norms so that insurance manufacturing licences are reserved for promoter-led entities, which pushes venture-backed insurtechs toward distribution-only models. The same package proposes market infrastructure institutions and a marketplace model with a fee well below current commission rates. In other words, the direction of travel is to move distribution onto infrastructure that a regulator licenses and a marketplace prices, while the start-up route to becoming an insurer is being narrowed.
  • Vertical integration by intermediaries is a different thing from competition by intermediaries. If a platform sells policies from several insurers and earns a spread between price and commission, it has an incentive to show you options. If it also manufactures the product, its incentive is to steer you to its own. Nothing in the draft rules prevents that; the proposed commission disclosure and seller tagging would simply make it visible.
  • Cost optimisation and diversification are not the same strategy. Cutting to profitability preserves a business model that the draft is designed to compress. Moving into credit life, own manufacturing or adjacent revenue changes the model. Which one a platform chooses will be visible in its licence applications and in what it stops selling.
  • For a policyholder, the practical consequence is fewer independent price comparisons. The comparison layer is where commission costs used to be absorbed. If that layer consolidates into a handful of groups that also manufacture, the argument for checking a second channel before you buy becomes stronger, not weaker.

Action

Do not treat a platform's scale as evidence of a better price. The cheapest quote on a comparison page and the quote that survives a hard commission cap are different products, and the second is the one you will be renewing. Before you buy, check the premium against the insurer's own website and against one other channel, and if you are quoted a policy through an app, ask which insurer underwrites it and whether the seller earns anything from the product you are shown. If you are an intermediary, the useful question to answer now is which parts of your revenue are commission on a product the draft caps and which are fees for work the draft does not price. Watch item: any licence application from a platform-backed entity, and whether IRDAI grants a formal path from distribution into manufacturing, which the Coverfox letter has asked for and which would materially change the competitive picture.